Elias Issa, MD
Internal Medicine · Blue Ridge, GANPI 1053305888
Payments from drug & device makers
Across 284 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$748
- Boehringer Ingelheim$569
- Grifols USA, LLC$554
- Mylan Specialty L.p.$495
- Sunovion Pharmaceuticals Inc.$286
- AstraZeneca$268
- plus $1K from 30 others
What the payments were for
- Food & beverage$4,24399%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $748 |
| Boehringer Ingelheim | 34 | $569 |
| Grifols USA, LLC | 36 | $554 |
| Mylan Specialty L.p. | 35 | $495 |
| Sunovion Pharmaceuticals Inc. | 20 | $286 |
| AstraZeneca | 18 | $268 |
| Insmed, Inc. | 9 | $160 |
| Mallinckrodt Hospital Products Inc. | 7 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $101 |
| Pfizer | 5 | $79 |
| Eisai Inc. | 5 | $75 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Harmony Biosciences LLC | 3 | $68 |
| Advanced Respiratory, Inc | 4 | $66 |
| Circassia Inc. | 4 | $66 |
| Viatris Specialty LLC | 4 | $65 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Baxter Healthcare | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Shire North American Group Inc | 2 | $36 |
| Verona Pharma, Inc. | 2 | $32 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Johnson & Johnson | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Amgen | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Ambu Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$4,289 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 72 | $823,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,001 | $771,558 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 203 | $154,419 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 126 | $77,843 |
| OzempicSemaglutide | 31 | $40,451 |
| Spiriva RespimatTiotropium Bromide | 52 | $34,371 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,222 | $29,656 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $27,482 |
| Zileuton ErZileuton | 11 | $27,451 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $27,199 |
| EliquisApixaban | 40 | $25,752 |
| LinzessLinaclotide | 46 | $25,029 |
| JardianceEmpagliflozin | 27 | $18,181 |
| JanuviaSitagliptin Phosphate | 62 | $17,354 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $16,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $748 | $888,2711,210 claims |
| Grifols USA, LLCProlastin C | $554 | $823,46872 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $268 | $170,585259 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Jardiance, Combivent Respimat, Tradjenta | $569 | $94,185186 claims |
| Novo NordiskOzempic | $17 | $40,45131 claims |
| PfizerEliquis | $79 | $25,75240 claims |
| Johnson & JohnsonXarelto | $25 | $9,43217 claims |
| Eisai Inc.Dayvigo | $75 | $9,01927 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $6,11725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Blue Ridge
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.